ERBB2 and breast cancer: At the same time, DS8201 received expedited FDA approval for patients with unresectable or metastatic HER2-positive breast cancer who have undergone at least two anti-HER2-based treatment regimens in a metastatic setting, aligning closely with the current case under discussion.